Gout (Hyperuricemia) News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Examining the Connection Between Gout and Metabolic Syndrome - Rheumatology Advisor



Rheumatology Advisor
 
Examining the Connection Between Gout and Metabolic Syndrome 
Rheumatology Advisor
The prevalence of gout has increased substantially in recent years, and most individuals with the disease are not getting the recommended treatment.1 Additionally, there is increasing evidence linking hyperuricemia with the promotion of hypertension ...

 


Gout and Stem Cell Therapy - Checkbiotech.org (press release)



Checkbiotech.org (press release)
 
Gout and Stem Cell Therapy 
Checkbiotech.org (press release)
A gout is a form of arthritis. It can be defined as a form of arthritis disease that causes the development of inflammation in the joints. This usually begins in one joint, then spreads to other parts. It causes the joint to appear red, swollen, hot ...

 


Comparing Immunomedics (NASDAQ:IMMU) & Ironwood Pharmaceuticals (IRWD) - StockNewsTimes



The Ledger Gazette
 
Comparing Immunomedics (NASDAQ:IMMU) & Ironwood Pharmaceuticals (IRWD) 
StockNewsTimes
About Ironwood Pharmaceuticals. Ironwood Pharmaceuticals logo Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C ...
Ironwood Pharmaceuticals (IRWD) Stock Rating Upgraded by BidaskClub The Ledger Gazette
Ironwood Pharmaceuticals (NASDAQ:IRWD) Earning Somewhat Positive News Coverage, Study Shows Dispatch Tribunal
$86.70 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter The Lincolnian Online
Thorold News  -BangaloreWeekly 
all 20 news articles » 


Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up - Nasdaq



Nasdaq
 
Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up 
Nasdaq
Zurampic and Duzallo, approved for uncontrolled gout, generated sales of $1.6 million in the quarter. In August, the FDA approved Duzallo as an oral treatment for hyperuricemia associated with gout in patients. The drug was launched in October 2017 ...

and more » 


FDA Approves First Fixed-Dose Combo Treatment for Hyperuricemia in Gout - Genetic Engineering & Biotechnology News



Rheumatology Advisor
 
FDA Approves First Fixed-Dose Combo Treatment for Hyperuricemia in Gout 
Genetic Engineering & Biotechnology News
The FDA has approved the first fixed-dose combination treatment designed to address in a single pill both causes of hyperuricemia in gout?overproduction and underexcretion of serum uric acid. Ironwood Pharmaceuticals will market DuzalloŽ (lesinurad ...
FDA Approves Duzallo for Hyperuricemia Associated With Uncontrolled Gout Rheumatology Advisor
FDA Approves Duzallo for Hyperuricemia in Uncontrolled Gout Managed Care magazine
FDA Clears First Fixed-Dose Combination Treatment for Gout Medscape
Pharmacy Times  -Business Wire (press release)  -Boston Business Journal 
all 30 news articles » 


Shanghai Fosun Pharmaceutical (2196) Is Yet to See Trading Action on Feb 21 - BZ Weekly



Shanghai Fosun Pharmaceutical (2196) Is Yet to See Trading Action on Feb 21 
BZ Weekly
Shanghai Fosun Pharmaceutical Co., Ltd., a healthcare company, engages in the research, development, manufacture, trade, and sale of pharmaceutical products in Mainland China and internationally. The company has market cap of $101.82 billion. It offers ...

and more » 


Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call - Business Wire (press release)



Business Wire (press release)
 
Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call 
Business Wire (press release)
We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS?C) or chronic idiopathic constipation (CIC), and lesinurad, which is ...
Brokers Set Expectations for Ironwood Pharmaceuticals, Inc.'s FY2022 Earnings (IRWD) Alive For Football
EPS for QEP Resources, Inc. (QEP) Expected At $-0.07; Ironwood Pharmaceuticals, Inc. (IRWD) Covered By 4 Bulls Norman Weekly

all 101 news articles » 


Ironwood Pharmaceuticals, Inc. (IRWD) Analysts See $-0.22 EPS - BZ Weekly



BZ Weekly
 
Ironwood Pharmaceuticals, Inc. (IRWD) Analysts See $-0.22 EPS 
BZ Weekly
The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in ...
Nektar Therapeutics (NKTR) and Ironwood Pharmaceuticals (IRWD) Critical Review StockNewsTimes
Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded by BidaskClub to ?Sell? The Lincolnian Online
FY2021 EPS Estimates for Ironwood Pharmaceuticals, Inc. Raised by Wedbush (NASDAQ:IRWD) The Ledger Gazette
Zacks 
all 111 news articles » 


Say it Right: Knowing yourself from inside out - Mail Tribune



Say it Right: Knowing yourself from inside out 
Mail Tribune
This term refers to body odor, often caused by sweat glands which are divided into two types, apocrine and eccrine (two words for another day). Many are familiar with the prefix hyper-, meaning higher, increased or excessive. Thus we see clearly the ...

 


Ironwood Pharmaceuticals (IRWD) Upgraded to Hold at Zacks Investment Research - StockNewsTimes



StockNewsTimes
 
Ironwood Pharmaceuticals (IRWD) Upgraded to Hold at Zacks Investment Research 
StockNewsTimes
Ironwood Pharmaceuticals logo Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by Zacks Investment Research from a ?sell? rating to a ?hold? rating in a research note issued to investors on Thursday, January 18th. According to Zacks, ?Ironwood's ...
Financial Newsletter - Zacks Zacks

all 38 news articles »